在体外、体内和体外从蛇毒中分离出血小板聚集抑制剂

M.A Zhelavskyi
{"title":"在体外、体内和体外从蛇毒中分离出血小板聚集抑制剂","authors":"M.A Zhelavskyi","doi":"10.15407/biotech16.05.055","DOIUrl":null,"url":null,"abstract":"Snake venom-derived platelet aggregation inhibitors can be promising antiplatelet medications that can allow to avoid the risk of bleeding and treatment resistance, particularly in aspirin-resistant patients. Our study aimed to assess the effectiveness of a platelet aggregation inhibitor derived from Echis multisquamatis snake venom in various settings, including in vitro, in vivo, and ex vivo. Methods. We examined a polypeptide from Echis multisquamatis venom, purified using a recently developed chromatography protocol, across multiple models. This polypeptide was introduced into platelet-rich blood plasma and administered intravenously to rats. The effects on platelet aggregation were assessed using aggregometry, focusing on ADP-induced aggregation. Results & Discussion. Our findings revealed that a concentration of 0.040 mg/ml significantly reduced platelet aggregation in vitro. Remarkably, this dosage also proved effective when administered intravenously in laboratory animals, reaffirming its potential as a robust antiplatelet agent. In the final phase of our study, the polypeptide demonstrated its ability to inhibit platelet aggregation in blood plasma of pregnant woman with aspirin resistance, presenting a promising avenue for innovative treatment approaches in such cases. Conclusion. This study underscores the potential of the Echis multisquamatis venom-derived polypeptide as a promising antiplatelet agent, effective in diverse scenarios, including aspirin resistance. Further research and clinical trials are imperative to fully harness its therapeutic potential.","PeriodicalId":9267,"journal":{"name":"Biotechnologia Acta","volume":"12 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"APROBATION OF PLATELET AGGREGATION INHIBITOR FROM ECHIS MULTISQUAMATIS SNAKE VENOM IN VITRO, IN VIVO AND EX VIVO\",\"authors\":\"M.A Zhelavskyi\",\"doi\":\"10.15407/biotech16.05.055\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Snake venom-derived platelet aggregation inhibitors can be promising antiplatelet medications that can allow to avoid the risk of bleeding and treatment resistance, particularly in aspirin-resistant patients. Our study aimed to assess the effectiveness of a platelet aggregation inhibitor derived from Echis multisquamatis snake venom in various settings, including in vitro, in vivo, and ex vivo. Methods. We examined a polypeptide from Echis multisquamatis venom, purified using a recently developed chromatography protocol, across multiple models. This polypeptide was introduced into platelet-rich blood plasma and administered intravenously to rats. The effects on platelet aggregation were assessed using aggregometry, focusing on ADP-induced aggregation. Results & Discussion. Our findings revealed that a concentration of 0.040 mg/ml significantly reduced platelet aggregation in vitro. Remarkably, this dosage also proved effective when administered intravenously in laboratory animals, reaffirming its potential as a robust antiplatelet agent. In the final phase of our study, the polypeptide demonstrated its ability to inhibit platelet aggregation in blood plasma of pregnant woman with aspirin resistance, presenting a promising avenue for innovative treatment approaches in such cases. Conclusion. This study underscores the potential of the Echis multisquamatis venom-derived polypeptide as a promising antiplatelet agent, effective in diverse scenarios, including aspirin resistance. Further research and clinical trials are imperative to fully harness its therapeutic potential.\",\"PeriodicalId\":9267,\"journal\":{\"name\":\"Biotechnologia Acta\",\"volume\":\"12 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-10-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biotechnologia Acta\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15407/biotech16.05.055\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnologia Acta","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15407/biotech16.05.055","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

蛇毒衍生的血小板聚集抑制剂是一种很有前景的抗血小板药物,可以避免出血风险和耐药性,尤其是对阿司匹林耐药的患者。我们的研究旨在评估从Echis multisquamatis蛇毒中提取的血小板聚集抑制剂在体外、体内和体外等不同环境中的有效性。研究方法我们在多种模型中研究了用最新开发的层析方案纯化的多鳞片蛇毒多肽。我们将这种多肽引入富含血小板的血浆中,然后给大鼠静脉注射。使用聚集测定法评估其对血小板聚集的影响,重点是 ADP 诱导的聚集。结果与讨论。我们的研究结果表明,0.040 毫克/毫升的浓度可显著降低体外血小板聚集。值得注意的是,这一剂量在实验室动物静脉注射时也被证明有效,这再次证实了它作为一种强效抗血小板药物的潜力。在我们研究的最后阶段,该多肽证明了其抑制阿司匹林耐药孕妇血浆中血小板聚集的能力,为此类病例的创新治疗方法提供了一个前景广阔的途径。结论这项研究强调了埃奇斯多蛇毒衍生多肽作为一种有前途的抗血小板药物的潜力,它对包括阿司匹林耐药在内的各种情况都有效。要充分发挥其治疗潜力,进一步的研究和临床试验势在必行。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
APROBATION OF PLATELET AGGREGATION INHIBITOR FROM ECHIS MULTISQUAMATIS SNAKE VENOM IN VITRO, IN VIVO AND EX VIVO
Snake venom-derived platelet aggregation inhibitors can be promising antiplatelet medications that can allow to avoid the risk of bleeding and treatment resistance, particularly in aspirin-resistant patients. Our study aimed to assess the effectiveness of a platelet aggregation inhibitor derived from Echis multisquamatis snake venom in various settings, including in vitro, in vivo, and ex vivo. Methods. We examined a polypeptide from Echis multisquamatis venom, purified using a recently developed chromatography protocol, across multiple models. This polypeptide was introduced into platelet-rich blood plasma and administered intravenously to rats. The effects on platelet aggregation were assessed using aggregometry, focusing on ADP-induced aggregation. Results & Discussion. Our findings revealed that a concentration of 0.040 mg/ml significantly reduced platelet aggregation in vitro. Remarkably, this dosage also proved effective when administered intravenously in laboratory animals, reaffirming its potential as a robust antiplatelet agent. In the final phase of our study, the polypeptide demonstrated its ability to inhibit platelet aggregation in blood plasma of pregnant woman with aspirin resistance, presenting a promising avenue for innovative treatment approaches in such cases. Conclusion. This study underscores the potential of the Echis multisquamatis venom-derived polypeptide as a promising antiplatelet agent, effective in diverse scenarios, including aspirin resistance. Further research and clinical trials are imperative to fully harness its therapeutic potential.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
34
审稿时长
20 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信